Depression and substance use disorders: Clinical comorbidity and shared neurobiology.
Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, United States.
Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, United States. Electronic address: [email protected]
- Published Article
International review of neurobiology
- Publication Date
Jan 01, 2021
Mood disorders, including major depressive disorder (MDD), are the most prevalent psychiatric illnesses, and pose an incredible burden to society, both in terms of disability and in terms of costs associated with medical care and lost work time. MDD has extremely high rates of comorbidity with substance use disorders (SUD) as many of the same neurobiological circuits and molecular mechanisms regulate the reward pathways disrupted in both conditions. MDD may induce SUDs, SUD may contribute to MDD development, or underlying vulnerabilities and common life experience may confer risk to developing both conditions. In this chapter we explore theories of MDD and SUD comorbidity, the neurobiological underpinnings of depression, overlapping cellular and molecular pathways for both conditions, and current treatment approaches for these comorbid conditions. Copyright © 2021 Elsevier Inc. All rights reserved.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 03/07/2021 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/33648671